-
Mashup Score: 15Director of Research - Chennai, Tamil Nadu (IN) - 26 day(s) ago
Applications are invited for the post of Director of Research at Cancer Institute (WIA), Chennai, India.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 144Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study) - 4 month(s) ago
PURPOSE The effectiveness of a dexamethasone (DEX)-free regimen for chemotherapy-induced nausea and vomiting (CINV) prophylaxis in patients receiving highly emetogenic chemotherapy (HEC) is not known. METHODS This was a double-blind, phase III trial designed to show the noninferiority of a DEX-free regimen (olanzapine, palonosetron, and fosaprepitant [OPF]) compared with the DEX-containing regimen (olanzapine, palonosetron, and DEX [OPD]). Chemotherapy-naïve patients age 18-80 years receiving single-day HEC were randomly assigned 1:1 to receive either the OPD regimen or the OPF regimen. The primary objective was to compare complete response (CR) rates for vomiting during the overall period (start of chemotherapy to 120 hours). Secondary objectives included CR for vomiting during the acute period (0-24 hours) and delayed period (24-120 hours), CR for nausea, and comparison of toxicities and patient-reported outcomes. RESULTS Three hundred forty-six patients received the study interventi
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Time to move away from Dexamethasone for prevention of chemotherapy induced nausea and vomiting (CINV). ✅ Phase 3 double blind RCT ✅ DEX free prophylaxis is effective ✅ Lesser side effects like insomnia https://t.co/dnuHdYoFjC @JCOGO_ASCO
-
-
Mashup Score: 1Venkatraman Radhakrishnan: CTRT in locally advanced inoperable breast cancer - OncoDaily - 4 month(s) ago
Venkatraman Radhakrishnan: CTRT in locally advanced inoperable breast cancer / Breast Cancer, cancer, Concurrent chemoradiation, OncoDaily, Oncology,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: CTRT in locally advanced inoperable breast cancer - @venkymd https://t.co/DevH40jJ5C #oncodaily #oncology #cancer #breastc…
-
-
Mashup Score: 47Effect of Neoadjuvant Concurrent Chemoradiation on Operability and Survival in Locally Advanced Inoperable Breast Cancer - 4 month(s) ago
Inoperable locally advanced breast cancers (LABCs) are treated with neoadjuvant chemotherapy. We studied the use of neoadjuvant concurrent chemoradiation (NACCRT) in patients with inoperable LABC.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
Concurrent chemoradiation (CTRT) is SOC in many cancers. Why not in breast cancer? We show that CTRT in locally advanced inoperable breast cancer increases operability, increases path CR, no increased toxicity, reduces treatment time. @IJROBP @ASTRO_org https://t.co/leHaS3Hs8W
-
-
Mashup Score: 43
Supportive Care in Cancer – This review is an update of the MASCC/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy,…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet-
MASCC ESMO anti-emetic guidelines for highly emetogenic chemotherapy, multi-day chemotherapy, and high dose chemotherapy. https://t.co/3dIEVbFb5G @CancerCareMASCC @myESMO #antiemetic #oncology
-
-
Mashup Score: 15Tata Memorial Centre-led project makes waves with promise to cut cancer drug costs by up to 99% - 8 month(s) ago
23 hospitals from National Cancer Grid, a network of over 250 cancer centres, pilot ‘pooled procurement’ to improve negotiability for high-value oncology and supportive-care drugs.
Source: theprint.inCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @cspramesh: This one is special... https://t.co/25JBxYFAHL
-
-
Mashup Score: 1GHN Partnerships WG Webinar, June 30, 2023 - 10 month(s) ago
Speaker: Dr. Venkataraman RadhakrishnanTopic: Chemotherapy-induced nausea and vomiting
Source: YouTubeCategories: Latest Headlines, Oncologists1Tweet-
RT @pho_india: https://t.co/iH4UOBhYHX For those who missed the excellent talk by @venkymd on #CINV in Pediatrics . Evidence based approac…
-
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
You must be logged in and have a current registration to access this session’s video and slides. If you think you should have access, please Sign In . If not, you can still get access via a purchase. This material on this page is ©2023 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
DEXA FATIGUE STUDY #ASCO 2023 https://t.co/O7XVkqHMOi https://t.co/N20MdgjgvX
-
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
You must be logged in and have a current registration to access this session’s video and slides. If you think you should have access, please Sign In . If not, you can still get access via a purchase. This material on this page is ©2023 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
CINV POD STUDY #ASCO2023 https://t.co/3kJVfDqoVi https://t.co/AyzjzqIeEq
-
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 12 month(s) ago
AuthorsVenkatraman RadhakrishnanCancer Institute (WIA), Chennai, IndiaVenkatraman Radhakrishnan, Kritthivasan Venkatakrishnan, Jayachandran Perumal Kalaiyarasi, Gangothri Selvarajan, Nizamudin Mahaboobasha, Paulson Vijaykumar Victor, Malarvizhi Anbazhagan, Deyva Manohari Sivanandam, Swaminathan RajaramanOrganizationsCancer Institute (WIA), Chennai, IndiaAbstract DisclosuresResearch…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Yes, we can omit dexamethasone for CINV prophylaxis for highly emetogenic chemotherapy. CINV POD (prophylaxis omitting dexamethasone) study results are out. #ASCO23 OPF (olanzapine, palonosetron and fosaprepitant) should be a standard of care. https://t.co/PKEe6ngIot https://t.co/099pXC2MyF
-
Vacancy for Director of Research, Cancer Institute (W.I.A), Chennai India. https://t.co/Aj2j2uLebF